SEARCH

SEARCH BY CITATION

References

  • 1
    Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929938.
  • 2
    Heneghan MA, McFarlane IG. Current and novel immunosuppressive therapy for autoimmune hepatitis. HEPATOLOGY 2002; 35: 713.
  • 3
    McFarlane IG. Pathogenesis of autoimmune hepatitis. Biomed Pharmacother 1999; 53: 255263.
  • 4
    Vergani D, Choudhuri K, Bogdanos DP, Mieli-Vergani G. Pathogenesis of autoimmune hepatitis. Clin Liver Dis 2002; 6: 727737.
  • 5
    Herkel J, Jagemann B, Wiegard C, Lazaro JF, Lueth S, Kanzler S, et al. MHC class II-expressing hepatocytes function as antigen-presenting cells and activate specific CD4 T lymphocyutes. HEPATOLOGY 2003; 37: 10791085.
  • 6
    Robin MA, Le Roy M, Descatoire V, Pessayre D. Plasma membrane cytochromes P450 as neoantigens and autoimmune targets in drug-induced hepatitis. J Hepatol 1997; 26( Suppl 1): 2330.
  • 7
    Muratori L, Parola M, Ripalti A, Robino G, Muratori P, Bellomo G, et al. Liver/kidney microsomal antibody type 1 targets CYP2D6 on hepatocyte plasma membrane. Gut 2000; 46: 553561.
  • 8
    Ma Y, Peakman M, Lobo-Yeo A, Wen L, Lenzi M, Gaken J, et al. Differences in immune recognition of cytochrome P4502D6 by liver kidney microsomal (LKM) antibody in autoimmune hepatitis and chronic hepatitis C virus infection. Clin Exp Immunol 1994; 97: 9499.
  • 9
    Yamamoto AM, Cresteil D, Boniface O, Clerc FF, Alvarez F. Identification and analysis of cytochrome P450IID6 antigenic sites recognized by anti-liver-kidney microsome type-1 antibodies (LKM1). Eur J Immunol 1993; 23: 11051111.
  • 10
    Muratori L, Lenzi M, Ma Y, Cataleta M, Mieli-Vergani G, Vergani D, Bianchi FB. Heterogeneity of liver/kidney microsomal antibody type 1 in autoimmune hepatitis and hepatitis C virus related liver disease. Gut 1995; 37: 406412.
  • 11
    Lapierre P, Hajoui O, Homberg JC, Alvarez F. Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis. Gastroenterology 1999; 116: 643649.
  • 12
    Muratori L, Cataleta M, Muratori P, Lenzi M, Bianchi FB. Liver/kidney microsomal antibody type 1 and liver cytosol antibody type 1 concentrations in type 2 autoimmune hepatitis. Gut 1998; 42: 7216.
  • 13
    Lenzi M, Manotti P, Muratori L, Cataleta M, Ballardini G, Cassani F, et al. Liver cytosolic 1 antigen-antibody system in type 2 autoimmune hepatitis and hepatitis C virus infection. Gut 1995; 36: 749754.
  • 14
    Ma Y, Okamoto M, Thomas MG, Bogdanos DP, Lopes AR, Portmann B, et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology 2002; 35: 658664.
  • 15
    Czaja AJ, Donaldson PT, Lohse AW. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. Am J Gastroenterol 2002; 97: 413419.
    Direct Link:
  • 16
    Gelpi C, Sontheimer EJ, Rodriguez-Sanchez JL. Autoantibodies against a serine tRNA-protein complex implicated in cotranslational selenocysteine insertion. Proc Natl Acad Sci U S A 1992; 89: 97399743.
  • 17
    Wies I, Brunner S, Henninger J, Herkel J, Kanzler S, Meyer zum Buschenfelde KH, et al. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet 2000; 355: 15101515.
  • 18
    McFarlane BM, Sipos J, Gove CD, McFarlane IG, Williams R. Antibodies against the hepatic asialoglycoprotein receptor perfused in situ preferentially attach to periportal liver cells in the rat. HEPATOLOGY 1990; 11: 408415.
  • 19
    Vento S, O'Brien CJ, McFarlane BM, McFarlane IG, Eddleston AL, Williams R. T-lymphocyte sensitization to hepatocyte antigens in autoimmune chronic active hepatitis and primary biliary cirrhosis. Evidence for different underlying mechanisms and different antigenic determinants as targets. Gastroenterology 1986; 91: 810817.
  • 20
    Vento S, O'Brien CJ, McFarlane IG, Williams R, Eddleston AL. T-cell inducers of suppressor lymphocytes control liver-directed autoreactivity. Lancet 1987; 1: 886888.
  • 21
    Wen L, Peakman M, Lobo-Yeo A, McFarlane BM, Mowat AP, Mieli-Vergani G, et al. T-cell-directed hepatocyte damage in autoimmune chronic active hepatitis. Lancet 1990; 336: 15271530.
  • 22
    Lohr H, Treichel U, Poralla T, Manns M, Meyer zum Buschenfelde KH, Fleischer B. The human hepatic asialoglycoprotein receptor is a target antigen for liver-infiltrating T cells in autoimmune chronic active hepatitis and primary biliary cirrhosis. HEPATOLOGY 1990; 12: 13141320.
  • 23
    Lohr H, Treichel U, Poralla T, Manns M, Meyer zum Buschenfelde KH. Liver-infiltrating T helper cells in autoimmune chronic active hepatitis stimulate the production of autoantibodies against the human asialoglycoprotein receptor in vitro. Clin Exp Immunol 1992; 88: 4549.
  • 24
    Treichel U, McFarlane BM, Seki T, Krawitt EL, Alessi N, Stickel F, et al. Demographics of anti-asialoglycoprotein receptor autoantibodies in autoimmune hepatitis. Gastroenterology 1994; 107: 799804.
  • 25
    Peters MG. Animal models of autoimmune liver disease. Immunol Cell Biol 2002; 80: 113116.
  • 26
    Jaeckel E. Animal models of autoimmune hepatitis. Semin Liver Dis 2002; 22: 325338.
  • 27
    Voehringer D, Blaser C, Grawitz AB, Chisari FV, Buerki K, Pircher H. Break of T cell ignorance to a viral antigen in the liver induces hepatitis. J Immunol 2000; 165: 24152422.
  • 28
    Lapierre P, Djilali-Saiah I, Vitozzi S, Alvarez F. A murine model of type 2 autoimmune hepatitis: Xenoimmunization with human antigens. HEPATOLOGY 2004; 39: 10661074.
  • 29
    Yamauchi K, Yamaguchi N, Furukawa R, Takatsu K, Nakanishi T, Ishida K, et al. A murine model of acute liver injury induced by human monoclonal autoantibody. HEPATOLOGY 2005; 42: 149155.
  • 30
    Yamauchi K, Yamaguchi N, Furukawa T, Takatsu K, Nakanishi T, Sasaki M, et al. A novel IgM class autoantibody to a hepatocyte-related 190 kDa molecule in patients with type 1 autoimmune hepatitis. HEPATOLOGY 2004; 40: 687692.
  • 31
    Lefkowitch JH, Apfelbaum TF, Weinberg L, Forester G. Acute liver biopsy lesions in early autoimmune (“lupoid”) chronic active hepatitis. Liver 1984; 4: 379386.
  • 32
    Pratt DS, Fawaz KA, Rabson A, Dellelis R, Kaplan MM. A novel histological lesion in glucocorticoid-responsive chronic hepatitis. Gastroenterology 1997; 113: 664668.
  • 33
    Uibo RM, Helin HJ, Krohn KJ. Immunological reactions to liver-specific membrane lipoprotein (LSP) in experimental autoimmune liver disease in rabbits. Clin Exp Immunol 1982; 48: 505512.
  • 34
    Hopf U, Jahn HU, Moller B, Stemerowicz R, Wittenbrink C, Klein R, et al. Liver membrane antibodies (LMA) recognize a 26-kD protein on the hepatocellular surface. Clin Exp Immunol 1990; 79: 5461.
  • 35
    Vergani D, Wells L, Larcher VF, Nasaruddin BA, Davies ET, Mieli-Vergani G, et al. Genetically determined low C4: a predisposing factor to autoimmune chronic active hepatitis. Lancet 1985; 2: 294298.
  • 36
    Scully LJ, Toze C, Sengar DP, Goldstein R. Early-onset autoimmune hepatitis is associated with a C4A gene deletion. Gastroenterology 1993; 104: 14781484.
  • 37
    Doherty DG, Underhill JA, Donaldson PT, Manabe K, Mieli-Vergani G, Eddleston AL, et al. Polymorphism in the human complement C4 genes and genetic susceptibility to autoimmune hepatitis. Autoimmunity 1994; 18: 243249.